1

### 1 Title

- 2 Diagnostic accuracy of point-of-care testing (POCT) devices for postpartum haemorrhage: A
- 3 protocol of a systematic review and meta-analysis
- 4

# 5 Author names and affiliations

- 6 Eishin Nakamura<sup>1,2</sup>, Takahiro Mihara<sup>1</sup>, Yuriko Kondo<sup>1</sup>, Hisashi Noma<sup>3</sup>, Sayuri Shimizu<sup>1</sup>
- <sup>7</sup> <sup>1</sup>Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 8 Yokohama, Japan
- 9 <sup>2</sup>Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
- 10 University, Saitama, Japan
- <sup>3</sup>The Institute of Statistical Mathematics, Tokyo, Japan
- 12

### 13 Author list

- 14 1. Eishin Nakamura
- 15 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 16 Yokohama, Japan
- 17 Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
- 18 University, Saitama, Japan
- 19 2. Takahiro Mihara
- 20 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 21 Yokohama, Japan
- 22 3. Yuriko Kondo
- 23 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 24 Yokohama, Japan
- 25 4. Hisashi Noma
- 26 The Institute of Statistical Mathematics, Tokyo, Japan
- 27 5. Sayuri Shimizu
- 28 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 29 Yokohama, Japan
- 30

# 31 Corresponding author

- 32 Takahiro Mihara
- 33 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 34 Yokohama City University
- 35 22-2 Seto, Kanazawa-ku, Yokohama, Kanagawa
- 36 Tel: 81-45-787-2311

- 37 E-mail: meta.analysis.r@gmail.com
- 38 Keywords: postpartum haemorrhage, point-of-care testing devices, hypofibrinogenaemia

39

40

## 3

#### 41 ABSTRACT

#### 42 Introduction

In postpartum haemorrhage (PPH), coagulation factors, mainly fibrinogen, are exhausted early during the course of the disease, which can easily lead to disseminated intravascular coagulation (DIC) and cause maternal mortality. Although some studies have reported the efficacy of point-of-care testing (POCT) devices in detecting hypofibrinogenaemia, little research has been conducted on their usefulness in the diagnosis of PPH. We plan to perform a systematic review of the diagnostic accuracy of existing POCT devices for the diagnosis of hypofibrinogenaemia in PPH.

### 49 Methods and analysis

50 We plan to identify studies using POCT devices for PPH and perform a systematic review and 51meta-analysis of their accuracy of diagnosing hypofibrinogenaemia. The results of fibrinogen 52 measurements using the conventional Clauss method are used as reference standards. Literature 53 searches will be conducted using electronic databases (MEDLINE, Embase, Cochrane Database, and 54 Web of Science), and two reviewers will screen independently from the search results. The eligible 55 literature will be used to synthesise true positive, false positive, true negative, and false negative 56 results for the diagnosis of hypofibrinogenaemia. We will estimate the diagnostic accuracy of POCT 57 devices for diagnosing hypofibrinogenaemia in patients with PPH using the Reitsma-type bivariate 58 random-effects synthesis model and the hierarchical summary receiver operating characteristic 59 curve.

### 60 Ethics and dissemination

This systematic review will be conducted through the secondary use of literature extracted from electronic databases. There are no ethical issues associated with this research. The final integrated results will be submitted to a peer-reviewed journal.

#### 64 **Protocol registration**

- 65 The study protocol was registered with University Hospital Medical Information Network Clinical
- 66 Trials (UMIN000048272) and PROSPERO (CRD42023394785).

### 67 Strengths and limitations of the study

- Studies on the usefulness of POCT devices in the diagnosis of PPH are limited. Our study
   will perform a systematic review of the diagnostic accuracy of existing POCT devices for
   the diagnosis of hypofibrinogenaemia in PPH.
- 71
- The study will estimate the diagnostic accuracy of POCT devices using the Reitsma-type
   bivariate random-effects synthesis model and the hierarchical summary receiver operating
   characteristic curve.
- 75

4

76 77 78 79 80	•	The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT devices used may vary between studies and could be a potential source of heterogeneity. Since most primary studies are observational, it is expected that many unpublished studies will exist.
81 82 83 84 85	•	The applicability of the study results may be limited since this systematic review only pertains to the use of POCT devices in pregnant patients with PPH. The number of studies may be limited since there is a wide variety of POCT devices used in PPH.
86 87		

5

#### 88 INTRODUCTION

#### 89 Background

90 Postpartum haemorrhage (PPH) causes massive blood loss during labour and is one of the leading 91 causes of maternal death.(1) PPH often presents with severe coagulopathy complicated by 92 disseminated intravascular coagulation (DIC). The level of fibrinogen in the blood, which is 93 considered the first to fall below the haemostatic threshold is particularly important, and blood 94 fibrinogen levels correlate with the severity of PPH.(2) Early diagnosis of hypofibrinogenaemia and 95 the initiation of transfusion therapy are important for improving maternal outcomes.

96 Conventional fibrinogen testing using the Clauss method is time-consuming and expensive to be 97 installed in primary medical facilities. In recent years, point-of-care testing (POCT) devices that 98 simply estimate blood coagulation function have been used as an initial treatment for PPH, and there 99 are reports of their usefulness in PPH.(3) Moreover, the POCT device allows for rapid testing at a 100 low cost, and the test results correlate well with fibrinogen levels in conventional blood tests.(4) 101 Although many reports on the effectiveness of POCT devices in clinical practice have been 102 recognised in the fields of cardiovascular surgery(5) and emergency medicine(6), there are limited 103 reports on their use in PPH. Since PPH has a different mechanism than other haemorrhagic diseases 104 such as trauma or cardiac surgery, the usefulness of POCT in other diseases may not be directly 105 applicable.

Early diagnosis of coagulopathy, especially hypofibrinogenaemia, in patients with PPH, and appropriate transfusion therapy may contribute to decreased total blood loss and mortality. Hence, early diagnosis of coagulopathy using POCT devices is important for improving the prognosis of PPH.

110

#### 111 **Clinical role of the index test**

In clinical practice, dry haematology, thromboelastography, and thromboelastometry are commonlyused POCT devices.

Dry haematology can directly and rapidly measure fibrinogen by measuring the viscosity of the magnetic particle motion signal using scattered light and calculating the fibrinogen value from the absorbance.(7) Therefore, it is reasonable to use it for the diagnosis of PPH, in which fibrinogen levels are particularly important, among other coagulation factors.

118 Thromboelastography enables the comprehensive evaluation of coagulation and haemostatic

119 function, including the effect of platelets, using whole blood samples. For TEG6s®, the parameters

120 that could be measured as actual values are 1. reaction time (R), 2. Kinetics (K), 3. Angle, 4.

121 maximum amplitude (MA), 5. whole blood clot lysis index at 30 minutes after MA(Ly30), 6.

122 amplitude 10(A-10) and 7. Functional fibrinogen (FLEV), 8. Activated clotting time (ACT) (8).

123 TEG6s can simultaneously measure four different reagents: Citrated Kaolin (CK), Citrated Kaolin

6

124 with Heparinase (CKH), Citrated Rapid TEG (CRT), Citrated Functional Fibrinogen (CFF), and

125 Citrated Rapid TEG (CRT).

The measurement principle of thromboelastometry is similar to that of thromboelastography but requires a large number of reagents and pipetting steps. (9) Thromboelastography and thromboelastometry often investigate and report parameters that correlate more with fibrinogen values since direct fibrinogen measurement is not possible.(10)

130

### 131 **Objectives**

- 132 The Population, Index tests, and Target condition (PIT) framework(11) in this study is shown in
- 133 Table 1.(12)

	iework
--	--------

Population	Pregnant patients after 20 weeks gestation and postpartum patients.
Index tests	The following POCT devices are defined as index tests.
	1. Dry haematology
	2. Thromboelastography
	3. Thromboelastometry
Target condition	Hypofibrinogenemia in patients with PPH

135 POCT, point-of-care testing; PPH, postpartum haemorrhage.

The purpose of this study is to perform a systematic review of the diagnostic accuracy of POCT devices in diagnosing hypofibrinogenaemia in patients with PPH. The population, index test, and target conditions are presented in Table 1. The reference standard for diagnosing hypofibrinogenaemia will be based on fibrinogen levels measured using the conventional Clauss method, and the cut-off value for diagnosing hypofibrinogenaemia will be determined based on the values set in each individual study. Figure 1 shows the clinical flowchart of the included studies.

142

#### 143 Significance of this review

144 As mentioned above, there have been numerous reports on the usefulness of POCT devices in 145emergency medicine and cardiovascular surgery. However, there are few reports on their use in PPH. 146 Compared to non-pregnant women, pregnant women are characterised by circulatory dynamics and 147 blood coagulability. In pregnant women, the circulating blood volume is increased by up to 50%, all 148 coagulation factor activities except for factor 13 are increased, and the fibrinolytic system is 149 relatively suppressed.(12,13) Since fibrinogen requires the highest concentration of any coagulation 150factor during haemostasis, high-volume transfusion in the setting of PPH is easily complicated by 151 dilutional coagulopathy.(14,15) In addition, PPH consumes large amounts of coagulation factors to 152stop bleeding from the placental abruption site, which may result in consumptive coagulopathy.(16) 153 Since fibringen is the first to be consumed in these coagulation disorders, DIC progresses more

7

rapidly in PPH than in other haemorrhagic diseases. Therefore, given the unique aspects of pregnancy, it is necessary to investigate the effectiveness of POCT devices separately in patients with PPH.

- 157 If POCT devices demonstrate high diagnostic accuracy for detecting hypofibrinogenaemia in PPH,
- they can be used to guide treatment strategies for the early identification of coagulation disorders and appropriate transfusion therapy.
- 160

#### 161 METHODS AND ANALYSIS

This systematic review and meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the PRISMA-Diagnostic Test Accuracy (DTA) statement.(17,18) The study protocol was registered with University Hospital Medical Information Network Clinical Trials (UMIN000048272) and PROSPERO (CRD42023394785).

166

### 167 Eligibility criteria

168 Participants

169 Pregnant women and postpartum women after 20 weeks gestation and patients with blood loss 170 >1000 ml will be included. To examine the effectiveness of POCT devices in investigating the 171 parameters of bleeding in pregnant women, studies that only include pregnant women with 172 congenital coagulopathy will be excluded.

- 173 Setting
- 174 Studies in which the initial treatment for PPH or follow-up after transfusion was administered with
- 175 POCT will be included. Pilot studies conducted on healthy pregnant women and postpartum mothers
- 176 will be excluded.
- 177 index test
- 178 Only studies using Dry haematology (e.g. CG02N®), Thromboelastography (e.g. TEG®), or
- 179 Thromboelastometry (e.g. ROTEM®) as an index test will be included.
- 180 reference standard

181 Only studies that use the Clauss method for fibrinogen measurement as the reference standard will

182 be included. There are three methods for measuring fibrinogen in blood: the Clauss method, the salt

- 183 precipitation method, and the immunoassay method. The Clauss method is the most widely used
- 184 internationally, and studies using salting-out and immunoassay methods are excluded.(19) A low
- 185 blood fibrinogen level in pregnant women is reported to be a risk for PPH at ≤200 mg/dl and a risk
- 186 for requiring massive blood transfusions at  $\leq$ 130–155 mg/dl.(20–22) The definition of
- 187 hypofibrinogenaemia is inconsistent in the literature with fibrinogen  $\leq 150$  mg/dl and  $\leq 200$
- 188 mg/dl.(23) We plan to collect the literature regardless of the cut-off value of hypofibrinogenaemia

8

- and integrate the results, and we will conduct a subgroup analysis according to the cut-off value if
- 190 there are a sufficient number of studies (i.e.,  $\geq$  five studies) for each cut-off value.
- 191 target condition
- 192 This study will include only PPH patients diagnosed with hypofibrinogenemia.
- 193 Types of studies
- 194 Only studies involving humans will be included, and literature on animals will be excluded. Studies
- 195 will include randomised controlled trials (RCTs) and non-RCTs (non-randomised controlled trials,
- 196 split time-series analyses, before/after comparisons, cohort studies, and case-control studies).
- 197 Non-published studies (e.g. conference abstracts and clinical trial protocols) will also be included.
- 198

### 199 Information sources and search strategy

- 200 The literature will be searched using electronic databases such as MEDLINE, Embase, the Cochrane
- 201 Database, and Web of Science, and references to the corresponding literature will also be evaluated.
- 202 A literature search of these databases will be conducted on 15/06/2023.
- 203 The search formula for PubMed is shown below in Table 2.
- 204

 Table 2: The search strategy for PubMed

Search Number	Query
1	"postpartum hemorrhage"[MeSH Terms] OR (postpartum[tiab] AND hemorrhage[tiab])
1	OR (postpartum[tiab] AND haemorrhage[tiab])
2	"point of care testing"[MeSH Terms] OR "Point-Of-Care"[tiab] OR (point*[tiab] AND
2	care[tiab] AND test*[tiab])
3	dry[tiab] AND hematology[tiab]
4	"thrombelastography"[MeSH Terms] OR "Thromboelastometry"[tiab]
	"blood coagulation tests" [MeSH Terms] OR (blood[tiab] AND coagulation[tiab] AND
5	test*[tiab])
	"viscoelasti*"[tiab] AND ("haemostat*"[tiab] OR "hemostatics"[MeSH Terms] OR
0	"hemostasis"[MeSH Terms] )
7	#2 OR #3 OR #4 OR #5 OR #6 OR #7
8	#1 AND #7

205

# 206 Study selection

### 207 Data management and selection process

208 The list of references obtained from the electronic databases will be scanned using literature

209 management software (EndNote®) to remove duplicate references. The titles and abstracts will be

210 screened by two independent reviewers (EN and YK) to assess the inclusion criteria. For references

211 determined to be eligible by at least one of the two reviewers in the primary screening, we will

9

212 proceed to the secondary screening process using the full text. Secondary screening using the full 213 text will be conducted for references that qualify in the primary screening and for those that cannot 214 be determined to be eligible based on the title and abstract. Disagreements regarding the eligibility 215 for the study will be resolved through discussion.

216

### 217 Data collection process

Two independent reviewers (EN and YK) will extract data from the eligible literature. If there are discrepancies in data extraction between the two parties regarding the extraction of data, they will be resolved through discussion.

221

### 222 Data items

223 Maternal age at delivery, weeks of delivery, primiparity, maternal body mass index, method of 224 delivery (vaginal or cesarean), cause of PPH (atonic bleeding, perineal laceration, retained or 225 adhered placenta, placental abruption, amniotic fluid embolism), total blood loss, total blood 226transfusion requirements (Red Cell Concentrate, Fresh Frozen Plasma, Platelet Concentrate, 227 fibrinogen concentrate), maternal deaths, blood fibrinogen levels measured by the Clauss method at 228 the time of POCT device use, type of POCT device used, measurement results of POCT devices [(1) 229 dry-haematology: fibrinogen, (2) thromboelastography: R, K, MA, Ly30, A-10, FLEV, (3) 230 thromboelastometry: CT, CF, CFT, alpha, A10, MCF, LI30, LI60, ML], and the number of patients in 231 the true positive, false positive, true negative, and false positive will be collected as diagnostic 232accuracy for hypofibrinogenemia.

233

#### 234 **Outcomes and prioritization**

235 Primary outcome

The primary outcome is the diagnostic accuracy of the POCT device to determine hypofibrinogenemia. Hypofibrinogenemia is diagnosed based on the fibrinogen values measured

- 238 using the Clauss method.
- 239 Secondary outcomes
- 240 The secondary outcome is the correlation coefficient between the fibrinogen value measured using
- the Clauss method and the test values measured using POCT.
- 242

#### 243 **Risk of bias in individual studies**

244 QUADAS-2 (24) will be used to assess the risk of bias for each study; QUADAS-2 is classified into

- the following four domains: (1) participant selection, (2) index test, (3) reference standard, and (4)
- 246 flow and timing. For each domain, the risk of bias is classified as 'low', 'unclear', and 'high', and

10

concerns about applicability are also classified as 'low', 'unclear', and 'high'. Signalling questions are
also included to facilitate the evaluation of the risk of bias for each domain.

249

# 250 Data synthesis and meta-analysis

Firstly, we will present the predictive accuracy measures of individual studies based on the reported counts of true positives, false positives, false negatives, and true negatives; sensitivities and specificities will be calculated, accompanied by their corresponding 95% confidence intervals. Coupled forest plots will be used to visualize sensitivities and specificities of POCT for diagnosing hypofibrinogenaemia. In addition, scatter plots will be generated for pairs of sensitivities and specificities to perform exploratory evaluations and assess heterogeneity.

257 Secondly, we will perform synthesis analyses using Reitsma's bivariate random-effects model to 258 account for possible heterogeneities across studies based on study-specific sensitivities and 259 specificities.(25) The results will be the summary estimates of sensitivities and specificities, along with their heterogeneity variances ( $\tau^2$ ). Furthermore, we will generate summary receiver operating 260 261characteristic (SROC) curves(26) based on bivariate random-effects model estimates and report the 262 areas under the curves (AUCs) as a summary measure of diagnostic accuracy.(27,28) For statistical 263 inference, we will employ standard restricted maximum likelihood estimation for Reitsma's 264 model(25) and use the bootstrap method to calculate 95% confidence intervals for the AUCs of the 265 SROC curves.(29) We will also perform a generalised Egger test for multivariate meta-analysis to 266 assess potential publication bias.(30) Statistical analyses will be performed using R software (R 267Development Core Team, Vienna, Austria) and RStudio (RStudio, Boston, Massachusetts, USA).

268

#### 269 **Confidence of cumulative evidence**

270 Once sufficient results have been obtained, the Grading of Recommendations, Assessment,

271 Development, and Evaluations (GRADE) will be used to evaluate the certainty of evidence.(31)

272

#### 273 Subgroup analyses

If different thresholds for hypofibrinogenaemia are adopted among the eligible studies, subgroup analyses will be considered according to the prespecified clinically relevant thresholds ( $\leq$ 150 mg/dl,  $\leq$ 200 mg/dl). In addition, to evaluate possible heterogeneity, subgroup analyses will be performed based on the types of POCT devices used (dry haematology, thromboelastography, and thromboelastometry).

279

## 280 **DISCUSSION**

Early detection of hypofibrinogenaemia in PPH and appropriate coagulation factor replacement are crucial to improve the prognosis of PPH. However, no previous systematic review has reported the

11

283 usefulness of POCT devices in PPH. This systematic review focuses on the diagnostic accuracy of 284 POCT for hypofibrinogenaemia and may provide data for the effective use of POCT devices in PPH. 285This study will focus on blood fibrinogen levels in patients with obstetric haemorrhage. Fibrinogen 286 level is the most important coagulation index in the blood of patients with PPH. Although many 287 coagulation factors are necessary for haemostasis, fibrinogen is required in the highest concentration 288 in the blood.(32) When massive haemorrhage occurs due to PPH, high-volume intravenous infusion 289 to maintain blood pressure can easily lead to dilutional coagulopathy.(33) Furthermore, there is a risk 290 of consumptive coagulopathy, in which a large amount of coagulation factors is consumed to stop 291 bleeding from the placental abruption surface. Moreover, fibrinogen is also the first to be 292 consumed.(34) Therefore, it is reasonable to assume that early recognition of hypofibrinogenemia 293and appropriate blood transfusion therapy will improve the prognosis of PPH compared to other 294 massive haemorrhages.

295In PPH, early identification of hypofibrinogenaemia and administering fibrinogen concentrate may 296 reduce the total amount of blood transfusion required and improve the prognosis.(23) Early 297 diagnosis of hypofibrinogenaemia using POCT devices and the development of transfusion protocols 298 may improve maternal outcomes in PPH and conserve medical resources, including transfusion 299 products.(35) This systematic review aims to determine the effectiveness of POCT in the diagnosis 300 of hypofibrinogenaemia in patients with PPH. If POCT devices are reliable for accurately diagnosing 301 hypofibrinogenaemia and determining the minimum transfusion volume needed to correct 302 coagulopathy, they could potentially increase maternal survival rates and reduce the burden on 303 medical resources.

304

### 305 Limitations and implications

306 This systematic review has several limitations. First, the heterogeneity among the studies may be an 307 issue. The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT 308 devices used may vary between studies and could be a potential source of heterogeneity. Second, 309 since most primary studies are observational, it is expected that many unpublished studies will exist. 310 Third, the applicability of the study results may be limited since this systematic review only pertains 311 to the use of POCT devices in pregnant patients with PPH. Fourth, the number of studies may be 312 limited since there is a wide variety of POCT devices used in PPH. If there are insufficient reports 313 for each device, the results of all POCT devices may be combined, making it difficult to determine 314 the most effective device since there will be no direct comparison between the devices.

315

#### 316 ETHICS AND DISSEMINATION

This systematic review will finally be submitted for publication in a peer-reviewed journal. The data

used in this study do not include individual patient data, so there are no patient privacy concerns.

- 319 There are also no restrictions on the release of data. Any significant changes from this protocol will
- 320 be described in detail.
- 321

## 322 Acknowledgements

- 323 We would like to thank Editage (www.editage.com) for English-language editing.
- 324

# 325 Author contributions

- 326 Conceptualization: Ehisin Nakamura, Takahiro Mihara, Sayuri Shimizu
- 327 Methodology: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma
- 328 Supervision: Takahiro Mihara, Sayuri Shimizu, Hisashi Noma
- 329 Writing Original Draft Preparation: Eishin Nakamura
- 330 Writing Review & Editing: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma,
- 331 Sayuri Shimizu.

332

#### 333 Competing Interests

None declared.

335

## 336 Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

339

#### 340 Word count

341 3876 words

342

### 343 **References:**

- Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic
   analysis. Lancet Glob Health. 2014;2:e323–33.
- Era S, Matsunaga S, Matsumura H, et al. Usefulness of shock indicators for determining
  the need for blood transfusion after massive obstetric hemorrhage. J Obstet Gynaecol Res
  2015;41:39–43.
- 349 3. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometry guided fresh frozen
  plasma infusion for postpartum haemorrhage: OBS2, an observational study. Br J Anaesth
  2017;119:422–34.
- 4. Hayakawa M, Gando S, Ono Y, et al. Rapid evaluation of fibrinogen levels using the
  CG02N whole blood coagulation analyzer. Semin Thromb Hemost 2015;41:267–71.

13

Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin
 Thromb Hemost 2017;43:386–96.

6. Da Luz LT, Nascimento B, Shankarakutty AK, et al. Effect of thromboelastography
(TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion
guidance and mortality in trauma: descriptive systematic review. Crit Care. 2014;18:1–26.

359 7. Ogawa S, Tanaka KA, Nakajima Y, et al. Fibrinogen measurements in plasma and whole
360 blood: a performance evaluation study of the dry-hematology system. Anesth Analg.
361 2015;120:18–25.

362 8. Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol 2017;1646:533–43.

363 9. Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major
364 trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen
365 concentrate and prothrombin complex concentrate. Crit Care 2010;14:1–11.

Lloyd-Donald P, Churilov L, Cheong B, et al. Assessing TEG6S reliability between
 devices and across multiple time points: A prospective thromboelastography validation study. Sci
 Rep 2020;10:7045.

11. Leeflang MM, Davenport C, Bossuyt PM. Chapter 6: Defining the review question. 2022.

Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surg Clin North Am
 2008;88:391–401.

Hui C, Lili M, Libin C, et al. Changes in coagulation and hemodynamics during
pregnancy: a prospective longitudinal study of 58 cases. Arch Gynecol Obstet 2012;285:1231–6.

374 14. Zentai C, Van Der Meijden PEJ, Braunschweig T, et al. Hemostatic therapy using
375 tranexamic acid and coagulation factor concentrates in a model of traumatic liver injury. Anesth
376 Analg 2016;123:38–48.

15. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
 target for the management of acquired bleeding. Anesth Analg. 2012;114:261–74.

Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
 acute haematological management. Blood Rev 2009;23:167–76.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
 meta-analyses: the PRISMA statement. PLoS Med. 2009;6:336–41.

18. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al.
Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy
Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388–96.

386 19. Stang LJ, Mitchell LG. Fibrinogen. Methods in Molecular Biology. 2013;992:181–92.

20. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al.

388 Association between fibrinogen level and severity of postpartum haemorrhage: Secondary analysis

389 of a prospective trial. Br J Anaesth. 2012;108(6):984–9.

- fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal of Thrombosis and
  Haemostasis. 2007 Feb 1;5(2):266–73.
- Wang L, Matsunaga S, Mikami Y, Takai Y, Terui K, Seki H. Pre-delivery fibrinogen
  predicts adverse maternal or neonatal outcomes in patients with placental abruption. Journal of
  Obstetrics and Gynaecology Research. 2016 Jul 1;42(7):796–802.
- 396 23. Matsunaga S, Takai Y, Seki H. Fibrinogen for the management of critical obstetric
   397 hemorrhage. J Obstet Gynaecol Res. 2019 Jan 1;45(1):13–21.
- 398 24. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
- 399 QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern
- 400 Med. 2011 Oct 18;155(8):529–36.
- 401 25. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.
  402 Bivariate analysis of sensitivity and specificity produces informative summary measures in
  403 diagnostic reviews. J Clin Epidemiol. 2005;58:982–90.
- 404 26. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of 405 diagnostic test accuracy evaluations. Stat Med 2001;20:2865–84.
- 406 27. Leeflang MMG, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test
   407 accuracy. Ann Intern Med 2008;149:889–97.
- 408 28. Macaskill P, Gatsonis C, Deeks J, et al. Cochrane Handbook for Systematic Reviews of
  409 Diagnostic Test Accuracy.
- 410 29. Noma H, Matsushima Y, Ishii R. Confidence interval for the AUC of SROC curve and
  411 some related methods using bootstrap for meta-analysis of diagnostic accuracy studies. Commun
  412 Stat Case Stud Data Anal Appl 2020;7:344–58.
- 413 30. Hong C, Salanti G, Morton SC, et al. Testing small study effects in multivariate 414 meta-analysis. Biometrics. 2020;76:1240.
- 415 31. GRADE Working Group. Grading quality of evidence and strength of recommendations.
  416 BMJ. 2004;328:1490–4.
- 417 32. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood
  418 loss with plasma-poor red cell concentrates. Anesth Analg 1995;81:360–5.
- 419 33. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
  420 target for the management of acquired bleeding. Anesth Analg 2012;114:261–74.
- 421 34. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
  422 acute haematological management. Blood Rev 2009;23:167–76.
- 423 35. Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the
- 424 outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth 2018;44:50–6.
- 425

<sup>390 21.</sup> Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of

# 426 Figure legend:

427 Figure 1: clinical flowchart of postpartum haemorrhage (PPH) patients

428

429

